Insider Buying: AEON Biopharma (NASDAQ:AEON) Major Shareholder Buys $241,500.00 in Stock

AEON Biopharma, Inc. (NASDAQ:AEON) major shareholder Timothy Lynch acquired 1,150,000 shares of AEON Biopharma stock in a transaction that occurred on Wednesday, August 19th. The shares were bought at an average price of $0.21 per share, for a total transaction of $241,500.00. Following the transaction, the insider owned 6,500,000 shares of the company’s stock, valued at $1,365,000. This represents a 21.50% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

AEON Biopharma Price Performance

Shares of AEON traded down $0.00 during mid-day trading on Friday, reaching $0.19. The stock had a trading volume of 1,694,684 shares, compared to its average volume of 775,456. The firm has a market cap of $4.86 million, a price-to-earnings ratio of 1.07 and a beta of 0.65. The business’s fifty day moving average is $0.44 and its 200 day moving average is $0.78. AEON Biopharma, Inc. has a 52-week low of $0.18 and a 52-week high of $1.45.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on AEON shares. HC Wainwright reaffirmed a “buy” rating and set a $1.20 target price (down from $5.00) on shares of AEON Biopharma in a research note on Friday, August 14th. Lake Street Capital initiated coverage on shares of AEON Biopharma in a research report on Thursday, July 30th. They issued a “buy” rating and a $1.00 price target for the company. Finally, Zacks Research upgraded shares of AEON Biopharma to a “hold” rating in a research note on Wednesday, May 27th. Three research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, AEON Biopharma has an average rating of “Moderate Buy” and a consensus price target of $1.10.

Institutional Trading of AEON Biopharma

A hedge fund recently raised its position in AEON Biopharma stock. Geode Capital Management LLC boosted its position in shares of AEON Biopharma, Inc. (NASDAQ:AEON) by 27.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 60,134 shares of the company’s stock after buying an additional 13,061 shares during the period. Geode Capital Management LLC owned 0.51% of AEON Biopharma worth $66,000 as of its most recent SEC filing. 22.78% of the stock is currently owned by hedge funds and other institutional investors.

About AEON Biopharma

AEON Biopharma, Inc, formerly Allied Energy Corp., is a clinical‐stage biopharmaceutical company focused on developing and commercializing treatments for rare and orphan diseases. The company applies enzyme replacement and gene therapy platforms to address unmet medical needs in central nervous system and metabolic disorders. Its lead program, AES-103, is being developed as an enzyme replacement therapy for Crigler-Najjar syndrome, a hereditary condition characterized by high levels of unconjugated bilirubin.

Beyond AES-103, AEON Biopharma is advancing AES-201 for X-linked adrenoleukodystrophy (X-ALD), a progressive neurological disorder, and AES-104 for post–COVID-19 conditions, commonly referred to as “long COVID.” These programs are in preclinical or early clinical stages, with ongoing efforts to optimize delivery, evaluate safety profiles and establish proof of concept.